-
Disease Description
“Tourette syndrome is a rare disorder that causes people to make unusual movements or sounds, called “tics.” Common examples of tics include blinking and throat clearing. People with the disorder have little or no control over their tics. Many people with Tourette syndrome have mild symptoms, but some have more severe ones. Most people with Tourette syndrome start showing signs of the disorder before they are 11 years old. In about half of children with Tourette syndrome, the tics go away by the time they turn 18. Tics that continue into adulthood gradually improve over time in many people. But in some people, the tics return later in life.” - Uptodate.com
Prevalence
“In a meta-analysis of 13 studies that specifically assessed TS in children, the prevalence of TS was 7.7 per 1000 children (95% CI 3.9-1.51) [18]. The prevalence was higher in boys compared with girls (10.6 versus 2.5 per 1000).” - Uptodate.com
Current Treatment Options
“Children and adults with Tourette syndrome don’t need medical treatment unless their tics are severe. A person with Tourette syndrome might need treatment if he or she is having problems:
●Talking with other people
●Attending school or working at a job
●Doing everyday things such as bathing, dressing, and eating Treatments include:
●Medicines – Certain medicines used to treat different mental health conditions can lower the number of tics a person has.
●Botulinum toxin (brand name: Botox) – This is a medicine that is given by injection. It works by blocking or calming the nerve signals that make the muscles jerk or twitch.
●Habit reversal training – This treatment involves working with a therapist who teaches people with Tourette syndrome to recognize when they are about to have a tic. Then, the people train themselves to do a different movement that makes it hard to do the tic. This treatment is not available everywhere.” -uptodate.com
Evidence for and Proposed Mechanism for Cannabinoids Therapeutics
"Anecdotal reports have suggested beneficial effects of marijuana (Cannabis sativa) in TS. Sandyk and Awerbuch (2) reported that three TSpatients experienced a significant amelioration of symptoms when using marijuana. These 15- to 39- year-old male patients had noted an improvement of tic severity, urge to tic, self-mutilatory behaviour, attention span, hypersexuality and a generalized relaxation when they smoked half to two marijuana cigarettes per day. Hemming and Yellowlees (3) described a single case of a 36- year-old man who had reported that he had been symptom free for more than 1 year while he was taking one 'cone' of marijuana per night.
Retrospective chart review. Our results provide more evidence that marijuana improves tics and behavioural disorders in TS. It can be speculated that cannabinoids might act through specific receptors, and that the cannabinoid system might play a major role in TS pathology." -Emrich HM, et al. Treatment of Tourette’s Syndrome with Δ9-Tetrahydrocannabinol (THC): A Randomized Crossover Trial. Pharmacopsychiatry 2002; 35: 57-61
In Germany, a study conducted at the Medical School Hannover stated:
"Previous studies provide evidence that marijuana (Cannabis sativa) and Δ9-tetrahydrocannabinol (Δ9-THC), the major psychoactive ingredient of marijuana, respectively, are effective in the treatment of tics and behavioral problems in Tourette syndrome (TS). It, therefore, has been speculated that the central cannabinoid receptor system might be involved in TS pathology. However, in healthy marijuana users there is an ongoing debate as to whether the use of cannabis causes acute and/or long-term cognitive deficits. In this randomized double-blind placebo-controlled study, we investigated the effect of a treatment with up to 10 mg Δ9-THC over a 6-week period on neuropsychological performance in 24 patients suffering from TS. During medication and immediately as well as 5-6 weeks after withdrawal of Δ9-THC treatment, no detrimental effect was seen on learning curve, interference, recall and recognition of word lists, immediate visual memory span, and divided attention. Measuring immediate verbal memory span, we even found a trend towards a significant improvement during and after treatment. Results from this study corroborate previous data suggesting that in patients suffering from TS, treatment with Δ9-THC causes neither acute nor long-term cognitive deficits. Larger and longer-duration controlled studies are recommended to provide more information on the adverse effect profile of THC in patients suffering from TS."
-
Category
Critical Ailments -
Created
Thursday, 16 March 2017 -
Group admin
CBIS
American States University
*** Warning this document contains graphic images.
Click the above Image to Review our Cancer Drug Comparables
Click the above Image to Review our 1-Million Strong FC, Media Kit
*** Warning this document contains exciting images.
Click the surrounding Images to become one of the First 1-Million Strong Killing Cancers, Fight Club Members to help 'Make that Change' Join in Now! *** Warning this Membership contains Exciting Results.
PS ... ALL of our CSi-VIP's, CSi-GIFT Share Recipients (Paid Processing Fees), CSi-Award Recipients, and those who Donated through the GO-Fund-Me Promotion are ALL Automatically included as "1-Million Strong Killing Cancers, Fight Club Members!"
You do not need to purchase anything, you are ALREADY included in the "First" 1-Million Membership Club, CONGRATULATIONS !!!
Please Click the Calendar image below to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
ALL of your PREVIOUS Cannabis Science (CBIS) Shares are on Record with the Company and with the Transfer Agent (As Confirmed by the SEC).
The Company does NOT have your Original trading CBIS Shares, either you have them, or your Brokerage Firm has them (with new identifier codes) or the Transfer Agent has them.
You can confirm with your Broker (Please obtain an Official Brokerage Firm Letter Representing where your CBIS shares are).
Your CBIS GIFT Shares are on Record Books with the Company and/or in your possesion for Regulatory submissions, Registered Legal Opinion Letters, and awaiting Final Audit for Final Trading approvals.
Your CBIS Shares are legal tender and we are ALL waiting for the FINAL Confirmations for trading once the Audits and Legal Filings are completed.
*** We will announce the FINAL CBIS acquisition changes and Corporate Mergers once the filings are completed, so as long as you know where your CBIS Shares are, you are GOOD.
As clearly stated by Mr. Dabney "Our History is Building up into our Inaugural Event of our Lifetime, the Inaugural 1-Million Strong Killing Cancers, Fight Club, VIP Fundraiser Event, dubbed, 'Celebrities Raising $20 Million to Keep Killing Cancers' the Initiative is fueled further with the '1- Million Strong Killing Cancers, Variety Television Show' through the ASU 'Make that Change Campaign'. Hence the accumulation of 1-Million people donating $20 each, because we are ALL Celebrities in our own Rights.
This is More than enough Funding to begin our FDA Clinical Trials for our 'Low-Cost Cancer Drugs' to treat millions Worldwide that already has proven HARVARD Award Winning Cancer Killing Success!
AND
This is also PLENTY of Funding to bring ALL our CBIS Shares back trading again and follow through with our Original Complete Cannabis Science Share trading Game Plan, and We Win, once again. Hopefully we'll see you at the Event to help 'Make that Change'!"
Should you have any further questions regarding your CBIS Shares or additional Share Ownership, Please Click the above Calendar Link to book your time to speak with Mr. Dabney about "Your Final CSi-VIP Shareholder Legacy".
The ASU Digital Business HUB will be used as the main business student learning center. GBXI will be the main pivot point to spin out trading shares of all our Partner Public and Private Companies such as Cannabis Science, iCannabinoid, Thermic Science, LNC, LMG, and a few more old and new school surprises for our loyal shareholders. No one will be missed! A true Digital Business HUB for students, just as planned all along.
Each spinout company will give our GBXI registered shareholders additional pro-rata shares in each spinout company over and above their original shares in each entity. This provides the required shareholder base for each company required to trade and gives additional shares to all our loyal GBXI shareholders.
We call this “Compounding our Wealth” through extra spinout share participation for all our loyal GBXI shareholders. Each registered GBXI shareholder will receive additional shares of each spinout Company over and above their original shares to enjoy additional liquidity as each company begins to trade through the GBXI Digital Business HUB spinout process.
Click here to review the Report:
Case No. 2:17-CV-02271-KJM-JDP
Inspire, Dream, Change
YOUR DIGITAL ERA Personal & Business Access Learning HUB
Observational Studies
Cannabis Science Inc. "Shareholder Loyalty Gift Center of Excellence"
HARVARD Award Winning
CANCER Killing Success
1st HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
2nd HARVARD Award Winning
Stage 4 Lung Cancer Killing Article:
*** Please click image below.
*** PLUS
(3) other Cannabis Science
REAL WORLD Successes:
Stage 4 Breast Cancer
Skin Cancer
Karposis Sarcoma
Cannabis Science CEO, Presents …
The FINAL “CBIS GIFT Shares” Issuances!
DECEMBER 1, 2022, Cheers! & HAPPY HOLIDAYS !!!
ALL GIFT Shares 1, 2, & 3 being ISSUED !!!
LAST Steps:
Please confirm Yours NOW !!!
1. CONFIRM Correct Total Share Amount(s)
2. CONFIRM Correct Name(s) on CERTIFICATE
3. CONFIRM Correct Mailing Address
ASU/CSi-EDP-ECO-System
At it's FINEST !!!
WHICH ONE ARE YOU ??
Those who, MAKE things happen.
Those who WATCH things happen.
Those who WONDER what the ... HAPPENED ???
We can make this HAPPEN way FASTER Working as a TEAM !!!
WHAT Matters is how much you CARE about KILLING CANCERS ...
This is it ... We are ALL Here ... Now ... with a Bunch of Celebrities going on TV Worldwide to Start raising $20 Million to Keep Killing Cancers.
2023 Audit considerations NASDAQ.
Cannabis Science Inc.
Share Structure 2023
Par Value: $0.001 USD
Last Price: $0.00647 USD
OTC Markets.
Common Stock:
Authorized:
5,000,000,000
Issued:
2,521,095,296
Class A Common Stock
Authorized:
100,000,000
Issued:
0
Class B Common Stock
Authorized:
1,500,000,000
Issued:
0
Preferred Stock
Authorized:
1,000,000
Issued:
1,000,000
Sign up for a FREE Assessment to JOIN the UNIVERSITY Team or any ASU/CSi-EDP Team for whatever your AREA of Expertise is … then say no more… you already know.
You already know our Extensive LIST of GROUNDBREAKING Products.
1-Million STRONG TV Coverage, HARVARD Award Success.
TAKE YOUR PICK AND BECOME A PART OF HISTORICAL CHANGE
*** APPLY for FREE in CONFIDENCE and Success.
Each Product launch WE RELEASE will include Equity Participation according to standard salaries and share bonus structures.
EVERYONE sign up to add your STRENGTHS to OUR COMBINED SUCCESS and lets MAKE THIS HAPPEN NOW !!!
Activity Stream
November 19, 2024, It is CERTAINLY Time for another UPDATE !!!
We've been utterly swamped putting together our 1-Million Strong, VIP Cancer Killing,...
Show more
-
-
4-
-
3-
-
4